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Abstract 
Carbon dot (CD) is a recently discovered fluorescent nanoparticle that exhibits excellent 
optical properties while also displaying great biocompatibility. This thesis examines two 
applications of CD: development of self-illuminating CD and investigation of the ability of 
CD in crossing biological barriers. 
 
The self-illumination of CD is achieved through bioluminescence resonance energy transfer 
(BRET) from a bioluminescent protein, Renilla luciferase, to CD. The synthesis of self-
illuminating CD consisted of using N’-(3-dimethylamnopropyl)-N-ethylcarbodiimide as 
coupler with 0.20 mg/mL to 0.80 mg/mL of CD and incubating with 2 M Rluc for 6.5 
hours. The BRET efficiency increased with increasing CD concentration. 
 
Bovine blood retina barrier (BRB), was used a biological barrier model. CD was incubated 
inside the eye after the removal of the vitreous. Preliminary data suggests that CD can cross 
the BRB as CD was found in the retinal neural layer of BRB as well as the choroid layer of 
BRB after treatment. 
Keywords 
Carbon dot, Renilla luciferase, bioluminescent protein, bioluminescence resonance energy 
transfer, biological barrier, blood retina barrier 
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Summary for Lay Audience 
Carbon dot (CD) is a nano sized synthetic material that was recently discovered. Because CD 
can fluoresce brightly, it has been mostly used to substitute less bright traditional dyes in 
bioimaging. As CD was recently discovered, the potential applications of CD have not been 
investigated thoroughly. The thesis consists of two studies: development of self-illuminating 
carbon dot and investigation if CD can cross biological barriers. 
 
Although CD can fluoresce brightly, the major downside is that an external light source has 
to excite CD for its fluorescence. The external light source can result in inaccuracy in results 
and damage to samples as the light is very powerful. Self-illumination was achieved by 
conjugating a bioluminescent protein, Renilla luciferase (Rluc), to CD. Rluc fluoresces when 
its substrate, coelenterazine, is present; the fluorescence from Rluc can excite CD so that it 
fluoresces. Such mechanism is referred to as bioluminescence resonance energy transfer 
(BRET). The study found that the synthesis of self-illuminating CD consists of a coupler, N’-
(3-dimethylamnopropyl)-N-ethylcarbodiimide, to help with the conjugation, 0.2 mg/mL to 
0.8 mg/mL of CD and incubating it with 2M of Rluc for 6.5 hours. The BRET efficiency 
was found to increase with increasing CD concentrations. Self-illumination eliminates the 
disadvantages of external light source while maintaining the bright fluorescence of CD. 
 
Biological barriers are physical barriers that exists to closely monitor what goes in and out of 
the most important parts of the body such as the brain and the eye; only extremely small or 
very specific materials can therefore enter and exit the biological barriers. Because it is easier 
to access intact eye structure compared to the brain, cow eyes were used to represent 
biological barriers. After incubating CD inside the eyes, both the retinal neural layer, the 
inside layer of the eye, and the choroid layer, the outside layer of the eye, had fluorescence 
after treatment, which suggests that CD might be able to cross BRB. With CD potentially 
crossing BRB, further studies can be done within the medical field to investigate and treat 
diseases that occur across the barriers. 
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Chapter 1  
1 Introduction 
1.1 Fluorescent Nanoparticles 
The world of nanoparticles (NP) is broad, as all particles within the nano scale size, a 
range of 10–1000 nm, are categorized as nanoparticles [1]. Out of these nanoparticles, 
some have been shown to have unique chemical and optical properties, which have led to 
the subcategorization of fluorescent nanoparticles (FNP).  
After their discovery, FNPs have been used to substitute traditional organic dyes in 
fluorescence studies because they possess superior photostability, brighter fluorescence, 
and distinct size-dependency in fluorescence [2,3]. Although different technologies used 
in fluorescence studies have improved using different sensing modes with high 
sensitivities, the low absorption coefficients, short fluorescent lifetime, and weak 
signaling of organic dyes have been problematic in fluorescent studies [4]. Naturally, 
researchers were fast to substitute organic dyes with FNPs immediately following their 
discovery. Since then, different FNPs have been implemented in various fluorescence 
studies, from simple biolabeling to the development of fluorescent sensors [5–8]. 
Apart from these unique optical properties, FNPs are also useful as they have the 
potential to act as a scaffold for domain addition in target-specific studies [9,10]. With 
high surface-to-volume ratio, distinct spatial domains can be functionalized providing a 
high potential synthetic platform for different sensor systems [3]. The developments in 
the field of FNP have not only helped in fluorescent studies but have also opened a 
multitude of doors in the field of target-specific fluorescent studies, which are arguably 
more important within the biomedical field. 
FNPs can be further categorized based on their synthesis material, such as metal NPs, 
quantum dots (QD), and carbon dots (CD). Out of the different types of FNPs, quantum 
dots and carbon dots are of special interest as their characteristics can be controlled by 
manipulating different steps during synthesis [3,11]. Because QDs have been developed 
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before CDs, there are more studies focusing on the synthesis and characterization of 
different QDs [12,13]. However, despite its superior brightness and wide excitation and 
emission spectra, the major downfall of QD is its biotoxicity. As the materials used to 
synthesize QD most often include heavy toxic metals, although QDs are small in size, 
their toxicity cannot be ignored in in vivo studies. Such drawbacks have led to a 
development of new synthetic FNPs that could exhibit the strong optical capabilities of 
QD while also being biocompatible. 
1.2 Carbon Dots 
1.2.1 Introduction 
CDs are approximately spherical in shape with a diameter of less than 10 nm [14,15]. As 
the name indicates, CD core is primarily composed of carbon but other elements, such as 
nitrogen and oxygen, can also be present depending on the starting ingredient of CD. 
Unlike highly toxic QDs, CDs possess excellent biocompatibility as well as high water 
solubility, excellent optical properties, and potential for easy surface functionalization; 
moreover, in comparison to QD synthesis, CD synthesis is much simpler and more cost-
effective. They are also more inert within the biological microenvironment, which allows 
for further research and development within the field [16]. Because of their superiority 
over QDs, CDs have been of interest in in vivo technologies, including bioimaging, 
biosensors, and drug delivery. 
1.2.2 Synthesis of CD 
1.2.2.1 Top-down synthesis 
There are three different top-down methodologies for CD synthesis: laser ablation, arc 
discharge, and electrochemical approach. Only laser ablation will be discussed further as 
it is the most common and simplest form of CD top-down synthesis. 
Laser ablation refers to a method in which laser irradiates a carbon target in order to 
produce a CD. A study by Sun and his colleagues demonstrate CD synthesis where the 
carbon target was a mixture of graphite power and cement to obtain nano-sized carbon 
particles [17]. Although the resulting particles were not fluorescent, further treatment 
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with nitric acid with polyethylene glycol (PEG) resulted in 5 nm fluorescent CDs. 
Similarly, Hu and his colleagues used graphite flakes suspended in PEG solution as the 
carbon target to obtain CDs through laser ablation [18]. The resulting black solution was 
centrifuged to isolate the CDs, and the obtained CDs were shown to be fluorescent. It was 
also discovered that the size and microstructure of CDs could be controlled by 
manipulating pulse width of the millisecond-pulsed laser. Despite the simplicity of laser 
ablation, this synthetic approach is not efficient as it requires excess carbon target for CD 
synthesis; furthermore, the size of the CD is difficult to control, resulting in low product 
yield. 
1.2.2.2 Bottom-up synthesis 
There are various bottom-up methods for the synthesis of CDs: pyrolytic process, 
template method, microwave-assisted method, and chemical oxidation approach. Like 
laser ablation in top-down synthesis, the microwave-assisted method is arguably one of 
the simplest methods for CD synthesis overall and will be discussed further. 
The microwave-assisted method is not only simple but also convenient and rapid, 
resulting in functional CDs within a few minutes and with reasonable yield. Guan and his 
colleagues describe a synthetic method using folic acid molecule as carbon and nitrogen 
sources [19]. In summary, folic acid was dissolved in diethylene glycol then microwaved 
to obtain a red-brown suspension, which was dialyzed to obtain functional CDs. Another 
synthetic method is described by Qu and his colleagues in which citric acid was used as 
the carbon source and urea was used as the nitrogen source [20]. The substances were 
dissolved in distilled water and then microwaved to obtain a brown liquid, which was 
further processed using a vacuum oven to isolate the resulting functional CDs. In both 
studies, the product yield and quantum yield of the resulting CDs were improved 
compared to laser ablation method. 
1.2.3 Optical Properties of CD 
Although the size of the CD has been shown to have an effect on the optical properties of 
the CD, the exact mechanism of CD fluorescence is still unknown. Different theories 
have been brought forth to explain the fluorescence, including quantum size effect, 
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degree of surface oxidation, and surface functional groups [21]. Nevertheless, the 
fluorescent property of CDs has been demonstrated in many different studies; 
furthermore, CDs absorbing and emitting at different wavelengths have been recorded in 
numerous experiments with researchers manipulating CD size to obtain CDs with 
different fluorescent properties [16]. Interestingly, CDs also show strong absorption in 
the ultraviolet (UV) region; however, similar to fluorescence, the peaking pattern has 
been shown to be highly dependent on the size of the CD. 
It is important to note that due to the novelty of CDs, more studies must be done to 
further clarify the different properties of CDs. In particular, investigation of the 
mechanism of CD fluorescence should be focused on to improve optical performance of 
CDs in the future. 
1.2.4 Other Properties of CD 
1.2.4.1 Photostability 
Photostability refers to the ability of fluorescent material to be stable during continuous 
excitation. In general, CDs have shown excellent photostability, which is especially 
important in bioimaging. Wei and his colleagues have determined their CD to have 
superior photostability compared to the traditional fluoresceinisothiocyanate (FITC) dye, 
QD, and previously reported polymer NPs [22]. Similarly, Ge and his colleagues have 
also compared the photostability between CDs and FITC by observing fixed-cell images 
of CD or FITC labelled HeLa cells [23]. It has been reported that the fluorescence of the 
CD was still clearly detectable 120 minutes after laser irradiation, while the fluorescence 
of FITC was undetectable only 10 minutes after laser irradiation. 
1.2.4.2 Cytotoxicity 
The cytotoxicity, or rather the biocompatibility, of CDs has been of high interest as it 
directly tackles the major disadvantage of already commercially available QDs. A 
previous study by Liu and his colleagues have reported no significant toxic effects of 
CDs on Michigan Cancer Foundation-7 (MCF-7) and human colorectal adenocarcinoma 
(HT-29) cell models [24]. Both cell lines displayed signs of proliferation and viability 
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suggesting the biocompatibility of CD. Male CD-1 mice were used for in vivo 
investigations of CD biocompatibility. Certain functional indicators, including but not 
limited to alanine amino transferase (ALT) and uric acid (UA), were shown to be at 
similar levels when compared to control mice; furthermore, serum biochemistry assays 
suggested that high dosage CD did not result in significant toxic effects. Moreover, 
histopathological analyses also demonstrated that the organ structures of the CD-treated 
mice were normal and nearly identical to the control group mice. 
1.2.5 Applications of CD 
1.2.5.1 Bioimaging 
CDs have been reported for use in both in vitro and in vivo bioimaging, as they are an 
ideal dye candidate due to their strong fluorescence and low cytotoxicity. 
In in vitro settings, CDs have been shown to be gradually taken up by HeLa cells as well 
as MCF-7 cells. The translocation from the extracellular environment to the cytoplasm 
was shown to be dependent on the size of the CD as well as surface charge, chemistry, 
and temperature [25,26]. Previous studies have also shown that when CD is modified 
with ligands for membrane receptors, the modified CDs are much more readily taken up 
by different cell models [27]. 
Unlike in vitro studies, in vivo studies are much more sensitive, due to the fact that 
particle size, surface charge, low cytotoxicity and sufficient cell uptake are all important 
parameters in in vivo imaging [16]. A study by Yang and his colleagues reported that 
CDs continually emitted fluorescence when injected into mice; moreover, in general, 
subcutaneous injection led to slow diffusion and eventual accumulation in the liver, while 
intravenous injection led to excretion of the CD through urine [28]. These particles were 
shown to exhibit good biocompatibility and low cytotoxicity. 
1.2.5.2 Biosensor 
Because of the simplicity of surface modification and the benign property of CDs, they 
are also an ideal base for biosensor development. 
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Li and his colleagues were able to develop a DNA sensor using CDs to selectively detect 
nucleic acid [29]. The sensing DNA was absorbed onto the surface of the CD through π-π 
interaction, leading to fluorescence quenching of CD; however, once the sensing DNA 
hybridized with the target DNA, the π-π interaction between CD and sensing DNA was 
eliminated, thereby recovering CD fluorescence. 
Similarly, protein sensors have been made by modifying the CD surface with specific 
antibodies. Ma and his colleagues developed a recombinant CD by modifying the surface 
with antibodies against mucin 1 (MUC1) and MUC1 aptamer [30]. Due to the 
sandwiching interaction between MUC1, MUC1 antibody, and MUC1 aptamer, this 
interaction led to CD aggregation, ultimately resulting in fluorescence quenching of CD. 
This protein sensor was found to be sensitive as well as cost efficient and convenient. 
1.2.5.3 Drug Delivery 
Various studies have discussed the different uses of CDs in drug delivery systems. A 
study by Jing and his colleagues used CDs as a contrast agent to monitor release of drug 
real time [31]. CDs have also been used as a targeting domain for drug delivery using 
surface modification of the CD with a specific ligand for targeting [32,33]. Finally, CDs 
have also been used as nanocarriers for gene delivery where the DNA can be condensed 
on the surface of the CD for delivery [34]. Upon uptake by the cell, the cell showed 
higher gene expression of the corresponding DNA. 
1.3 Thesis Overview 
The thesis is comprised of a literature review followed by two separate investigations and 
then a final conclusion to consolidate the two studies. 
Chapter 2 focuses on the literature review. Background knowledge specific to each study 
is presented to introduce the two different investigations. 
Chapter 3 focuses on the development of the self-illuminating CD. This is the first of the 
two separate investigations in this thesis. 
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Chapter 3 focuses on the examination of the ability of the CD to cross biological barriers. 
This is the second of the investigations in this thesis. 
Chapter 4 consolidates the previous two chapters into one coherent conclusion; 
furthermore, limitations and future work for the two investigations are also discussed in 
this section. 
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Chapter 2  
2 Literature Review 
2.1 Literature Review for Chapter 3 
2.1.1 Fluorescence Resonance Energy Transfer 
Fluorescence resonance energy transfer (FRET) is a mechanism initiated by a high-power 
light source exciting a donor molecule. The excited molecule then loses some of its 
energy to heat while emitting the majority of excited energy as a photon. Due to the loss 
of energy to heat, the donor molecule emits a photon at a longer wavelength compared to 
the photon used to excite the donor molecule. This photon then excites the acceptor 
molecule where a similar phenomenon occurs, resulting in a photon being released at an 
even lower wavelength. Because FRET is a mechanism that uses resonance energy 
transfer, FRET is a distance-dependent mechanism where closer proximity of donor to 
acceptor results in better excitation of the acceptor molecule.  
FRET has been widely used in studies involving protein-protein interactions [35–37]; 
however, many of them suffer from limitations originating from the high-power light 
source, such as tissue autofluorescence, photobleaching, photocytotoxicity, and tissue 
damage [38]. Therefore, its use is limited to in vitro studies where photocytotoxicity and 
tissue damage are not of concern. Furthermore, the high-power light source may also 
introduce tissue autofluorescence and photobleaching, which results in inaccuracy. While 
the problem of tissue autofluorescence can be solved by the development of new FRET 
pairs, which utilize emission and excitation wavelengths that are not common in 
biological settings, the still-standing limitations stemming from the high-power light 
source cannot be ignored. 
In order to eliminate the high-power light source, different modifications have been made 
to the FRET mechanism; two mechanisms that have resulted from these modifications are 
chemical resonance energy transfer (CRET) and bioluminescence resonance energy 
transfer (BRET). 
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2.1.1.1 Chemical Resonance Energy Transfer 
CRET is initiated with a chemiluminescence reaction, where an electronically excited 
molecule drops its electron to the ground state while releasing the energy as light energy, 
i.e. a photon. The photon produced from the reaction then acts as the donor photon that 
excites the acceptor molecule, which then emits a photon at a different wavelength when 
bringing down its excited electron to ground state. 
While CRET is able to successfully occur without the high-power light source, it has its 
own limitations in a biological environment. The initial chemiluminescence reaction most 
often requires metallic ions or catalyst enzymes; moreover, cofactors may also be 
necessary for the reaction to take place. While such requirements are not troublesome in 
in vitro studies, they pose many limitations in in vivo studies. Metallic ions are mostly 
toxic and therefore have low biocompatibility. Catalyst enzymes and cofactors may have 
sufficient biocompatibility; however, the possibility of the molecules interacting and 
producing unwanted reactions in the biological microenvironment cannot be ignored. 
2.1.1.2 Bioluminescence Resonance Energy Transfer 
BRET obtains its donor photon from natural bioluminescent molecules found in fireflies, 
jellyfish, and other organisms. When the bioluminescent protein is exposed to its 
substrate, an enzymatic reaction is initiated. The protein acts as an enzyme, and while 
working on the substrate, it also produces a photon as a byproduct. An example of this 
enzymatic reaction, in which the Renilla luciferase (Rluc) is the bioluminescent protein 
and coelenterazine is the substrate, is visualized in Figure 1. This byproduct photon is 
used as the donor photon to excite the acceptor molecule, which in turn releases its own 
photon to escape the excited state.  
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Figure 1: Visual representation of the Renilla luciferase enzymatic reaction. 
Coelenterazine is the substrate. The enzymatic reaction results in a product, 
coelenteramide, but also a byproduct, blue light at 480 nm. 
As a derivative of FRET, BRET is highly distance-dependent: the donor molecule and 
acceptor molecule must be within 10 nm of one another for the energy transfer to occur. 
Also, because BRET derived from FRET, BRET is able to successfully substitute for 
FRET in previous studies that have utilized FRET. For example, in one previous study, a 
FRET dye-labeled probe was used to improve single-base mismatch discrimination in 
DNA detection [35]. Although this study was previously limited to in vitro study due to 
its need for external light source, such probe could be used in animal models if the FRET 
dye-labeled probe was BRET dye-labeled instead. As mentioned before, FRET has been 
used in many protein-protein interaction studies; therefore, the potential of BRET is just 
as widespread. 
Unlike CRET, BRET only requires the bioluminescent protein and its appropriate 
substrate for the mechanism to initiate. Because the bioluminescent protein and its 
substrate are naturally occurring in specific organisms, they often have good 
biocompatibility with limited chance of unwanted interactions within the biological 
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microenvironment, as long as the in vivo study is completed using an organism that does 
not naturally use said molecules. 
2.1.2 Bioluminescent Proteins 
Bioluminescent proteins are naturally occurring enzymes in bioluminescent organisms, 
such as fireflies and sea pansies. More recent bioluminescent proteins were engineered in 
the laboratory setting to decrease the size of the protein for better biocompatibility while 
heightening its fluorescence intensity for more intense fluorescence signaling. Different 
bioluminescent proteins usually have different substrates required to complete their 
enzymatic reactions, and generally, the ideal bioluminescent protein and its substrate pair 
differs depending on the application and the biological microenvironment of the study. 
Most known bioluminescent proteins fall under the luciferase family, which is a class of 
oxidative enzymes. The oxidation of luciferase results in an electron going from the 
excited state to its ground state while releasing the energy as a photon. This photon can 
then be used to excite other nearby molecules, as previously discussed. 
A summary of different bioluminescent proteins is shown in Table 1. 
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Table 1: Summary of bioluminescent proteins. 
Name Size (kDa) 
Emission 
(nm) 
Substrate 
Aequorin 22 469 Coelenterazine 
Bacterial luciferase (Lux) 
Alpha subunit: 40 
Beta subunit: 35 
490 
FMNH2, long-chain 
aliphatic aldehyde 
Firefly luciferase (Fluc) 61 562 D-luciferin 
Renilla luciferase (Rluc) 36 480 Coelenterazine 
Gaussia luciferase (Gluc) 19.9 480 Coelenterazine 
Vargular luciferase (Vluc) 
or Cypridina luciferase 
62 460 Coelenterazine 
Metridia luciferase 24 480 Coelenterazine 
Nano luciferase (Nluc) 19 460 Furimazine 
2.1.2.1 Aequorin 
Aequorin is a 22 kDa photoprotein that is naturally occurring in jellyfish Aequorea 
victoria; it emits blue light at 469 nm as a byproduct of its enzymatic reaction, which 
uses coelenterazine as its substrate [39,40]. Aequorin is often used to detect calcium 
concentration due to its high sensitivity for calcium [41–43]. However, aequorin exhibits 
low light quantum yield in comparison to other bioluminescent proteins; furthermore, its 
substrate, coelenterazine, is unstable and has poor biodistribution [44]. 
2.1.2.2 Bacterial Luciferase 
Bacterial luciferase (Lux) consists of two subunits: alpha and beta, which are 40 kDa and 
35 kDa respectively [45]. Lux is an ATP-dependent luciferase and requires oxygen and 
NADPH as a cofactor in order for its enzymatic reaction to take place; long-chain 
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aliphatic aldehydes and flavin mononucleotides (FMNH2) are its substrates, while the 
byproduct is blue light at 490 nm [46]. Like aequorin, Lux exhibits poor light quantum 
yield as well as poor thermostability [47]. Furthermore, studies with Lux are limited to 
luminous bacteria due to the cytotoxicity of the long-chain aliphatic aldehydes [48]. 
2.1.2.3 Firefly Luciferase 
Firefly luciferase (Fluc) is a 61 kDa protein that is naturally occurring in fireflies; it emits 
blue light at 562 nm as a by-product after enzymatic reaction using D-luciferin [49,50]. 
Similar to Lux, Fluc is also ATP dependent and requires oxygen and magnesium as 
cofactors for its enzymatic reaction [50]. As the first luciferase to be discovered, Fluc has 
been extensively used in various studies across different fields; most notably, Fluc has 
been used to develop an ATP sensor, which takes advantage of the protein’s ATP-
dependency [51]. However, although Fluc exhibits higher light quantum yield in 
comparison to Lux and aequorin, D-luciferin does not display good biodistribution and 
has low affinity for Fluc [44]. As well, the large size of Fluc has been shown to lead to 
steric hindrance when developing recombinant proteins [52]. 
2.1.2.4 Renilla Luciferase 
Renilla luciferase (Rluc) is a 36 kDa bioluminescent protein that is naturally occurring in 
the sea pansy, Renialla reniformis. Rluc uses coelenterazine (CTZ) as its substrate and 
generates blue luminescence at 480 nm, which falls within the excitation range of CDs. 
Because Rluc originates from a non-mammalian organism, certain codons used in Rluc 
expression are uncommon in mammalian cells, which limits Rluc expression in 
mammalian cells [53]. Rluc is well adapted in different scientific studies and has been 
used as marker for gene expression and a biosensor for certain proteins [54]. 
2.1.2.5 Gaussia Luciferase 
Gaussia luciferase (Gluc) is a 19.9 kDa bioluminescent protein that originates from 
Gaussia princeps, a type of copepod [55]. Similar to Rluc, it also produces blue light at 
480 nm and uses coelenterazine as its substrate. It has also been characterized to be more 
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sensitive compared to Fluc and Rluc; however, despite its the heightened sensitivity, the 
light quantum yield is low [44,56]. 
2.1.2.6 Vargula Luciferase 
Vargula luciferase (Vluc), also known as Cypridina luciferase, is a 62 kDa protein that is 
naturally secreted by a marine ostracod, Cyridina noctiluca [57,58]. It emits blue light at 
460 nm as a by-product of its enzymatic reaction with vargulin, also known as cypridina 
luciferin [58]. Like Rluc, Vluc has been previously used as a marker for mammalian gene 
expression, as well as a recombinant biosensor [58]. One advantage Vluc has over other 
bioluminescent proteins is its glow-type bioluminescence compared to others’ flash-type 
bioluminescence [57]. 
2.1.2.7 Metridia Luciferase 
Metridia luciferase is a 24 kDa protein that uses coelenterazine as its substrate and 
produces blue light at 480 nm similar to Rluc and Gluc [59,60]. Its low molecular mass is 
an advantage in the development of recombinant proteins; however, its low light quantum 
yield is a major disadvantage [59,59]. 
2.1.2.8  Nano Luciferase 
Nano luciferase (Nluc) is one of the smallest luciferases at 19 kDa and was synthetically 
developed in order to tackle different disadvantages of luciferases [61,62]. It uses a new 
substrate, furimazine, which exhibits lower background noise compared to 
coelenterazine, and emits blue light at 460 nm as by-product [52,61]. Not many studies 
have been conducted using Nluc as the molecule was recently developed. Nluc exhibits 
glow-type bioluminescence with a long half-life of 2 hours [62]. 
2.2 Literature Review for Chapter 4 
2.2.1 Biological Barriers 
2.2.1.1 Blood Brain Barrier 
The blood-brain barrier (BBB) is a physical barrier that maintains homeostasis within the 
central nervous system (CNS) by protecting it from toxins and metabolic fluctuations. It 
15 
 
is comprised mainly of endothelial cells with other supporting structures, such as brain 
capillaries, pericytes, astrocytes, and the basement membrane [63–67]. These structures 
work together to supply the brain with required nutrients, such as glucose and oxygen, for 
normal neural functioning, while preventing neurotoxins from entering the neural cavity. 
Because the brain is tightly packed with microvasculature, the neuronal cells are in close 
proximity to blood capillaries, which allows for fast delivery of substances once the BBB 
is crossed. 
One of the differences between the capillaries of the BBB compared to capillaries found 
elsewhere in the body is the lack of fenestration in the endothelial cells [65].  The lack of 
fenestration prevents the passive diffusion of hydrophilic substances crossing the BBB 
through paracellular transport; furthermore, the endothelial cells are tightly packed and 
only connected through tight junctions, which helps in the prevention of paracellular 
transport [64–66]. Moreover, the electrical resistance of brain endothelium is much 
higher than other endothelial cells, which introduces even further limitations in 
paracellular transport. Due to these structural limitations, all substances cross the BBB 
via transcellular transport. There are few exceptions: very small (less than 400 Da), 
lipophilic molecules are able to diffuse through the lipid bilayer of the cell membrane 
[65]. 
Due to the complexity of the BBB structure, various drugs are blocked and cannot be 
delivered to the brain in sufficient quantity. This presents difficulties in treating CNS 
diseases, such as Parkinson’s disease and Alzheimer’s disease [63,64]. Drug delivery via 
intracerebral implantation and intracerebroventricular infusion have been attempted; 
however, such delivery methods present limitations in the dosage of the drug as well as a 
potential passage for infection [66,68]; moreover, they are also invasive procedures, 
which may lead to potentially detrimental side effects as well as low quality of life for 
patients. Thus, researchers and clinicians have focused on using the pre-existing transport 
mechanism of BBB to deliver drugs to the brain. 
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2.2.1.2 Blood Retina Barrier 
Similar to the BBB, blood retina barrier (BRB) is also a physical barrier that exists to 
protect the retina. The BRB consist of inner BRB (iBRB) and outer BRB (oBRB). Figure 
2 illustrates a diagram of different layers of the BRB. The oBRB consists of a retinal 
pigment epithelial (RPE) cell layer and regulates the movement of macromolecules from 
the choroid to the sub-retinal space. The iBRB is similar to the BBB and is comprised of 
retinal endothelial cells lining the microvasculatures to maintain the blood vessel and 
preserve homeostasis. Also similar to the BBB, both layers consists of tight junctions, 
which allow for the restriction of paracellular diffusion of molecules [69]. 
 
Figure 2: Different layers of the BRB. The two layers of BRB, choroid layer and 
neural retina layer, are pictured. Note that the sclera and the vitreous are not part 
of the BRB structure. 
While damage to the BBB results in neurodegenerative diseases such as Alzheimer’s, the 
breakdown of the BRB is results in retinal diseases, such as age-related macular 
degeneration (AMD). Although antibody treatments are available for AMD, because of 
the selective nature of the BRB, treatments are given by direct intraocular injection into 
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the vitreous of the eye, which due to its invasive nature, may lead to severe side effects, 
such as retinal hemorrhage and detachment [69]. 
Previous studies have demonstrated multiple similarities between the BBB and the iBRB. 
Despite their different site-specific functions, their transport and permeation 
characteristics have shown to be similar [70,71]. As mammalian retina is readily 
available from nearby abattoirs, the BRB is more readily used to study different 
substances crossing the endothelial barrier. Said experimentations can then be used to 
hypothesize the ability of these substances to cross the BBB. 
2.2.2 Mechanism of BBB transport 
Substances cross the BBB by one of the following four transport mechanisms: passive 
diffusion, carrier-mediated transport, adsorptive-mediated transcytosis, and receptor-
mediated transport. 
2.2.2.1 Passive diffusion 
Passive diffusion is a transport mechanism that is only used by small lipid-soluble 
molecules. These molecules are able to freely diffuse across the BBB by lipid-mediated 
diffusion. There are not many known substances that use this transport mechanism due to 
the size limitation and the requirement to be lipophilic, which is an uncommon 
characteristic [65]. 
2.2.2.2 Carrier-mediated transport 
Carrier-mediated transport (CMT) is one of the most common transport mechanisms used 
to cross BBB. Substances enter the endothelial cells via their corresponding 
transmembrane protein on the cell membrane. An example of CMT is the transportation 
of glucose using glucose transporter type 1 (GLUT1). GLUT1 is able to recognize 
glucose, as well as mannose and galactose, and actively transport these substances 
through the BBB [72]. An example of drug delivery using CMT is the delivery of L-
DOPA, a drug for Parkinson’s Disease, via large neutral amino acid transporter type 1 
(LAT1) [73]. LAT1 typically transports phenylalanine, as well as ten other large neutral 
amino acids, through the BBB. 
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2.2.2.3 Adsorptive-mediated transcytosis 
Adsorptive-mediated transcytosis (AMT) takes advantage of the electrostatic interaction 
between positively charged ligands and the negatively charged cell membrane. It is 
mediated by clathrin-dependent endocytosis and is unidirectional from the blood to the 
brain [65]. 
2.2.2.4 Receptor-mediated transport 
Receptor-mediated transport (RMT) is the other most common transport mechanism. 
Instead of using a corresponding transmembrane protein as the transporter, peptide 
receptors on the cell membrane mediate the transcytosis of the ligands [65]. 
2.2.3 Nanoparticles in Crossing Biological Barriers 
Certain specific nanoparticles have shown their ability to cross the BBB. By coupling 
their BBB crossing abilities and their fluorescent properties, nanomaterials can be 
modified with specific motifs to act as contrasting agents when performing diagnostic 
imaging. Various studies have been done to verify their abilities in crossing the BBB and 
their effectiveness in their role in fluorescent imaging of the brain. 
In 2010, Kato and his colleagues demonstrated that bioconjugated QDs were able to cross 
the BBB to enter the brain parenchyma [74]. The cytotoxic QDs were first conjugated 
with captopril to improve their biocompatibility and then intraperitoneally administered 
to rats. After six hours, the QDs were found in various organs and tissues including the 
brain, although the biodistribution within the brain differed significantly across different 
rats. The study hypothesized that the smaller QDs were able to cross the BBB while the 
bigger QDs were unable. Although the exact transport mechanism is unknown, the study 
suggests the possibility of CMT or the small-sized QDs fitting through the gaps between 
astrocytic processes and the capillary endothelium. It is also important to note that the 
bioconjugated QD did not display signs of cytotoxicity during the six hour period in 
which the rats were kept alive [74]. 
In 2014, Liu and his colleagues investigated the size dependency of silica nanoparticles 
when crossing the BBB [75]. The study was first proposed from an older study where 
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small gold nanoparticles (Au-NPs) were accidentally found to be able to cross the BBB 
while the larger Au-NPs could not [76]. The study by Liu used an in vitro BBB model 
with a 12-hour incubation period and reported that while all nanoparticles were able to 
cross the BBB, smaller nanoparticles crossed at a higher concentration compared to 
larger ones. The study was expanded into an in vivo rat model where similar results were 
shown, with smaller nanoparticles taking less time to cross compared to their larger 
counterparts [75]. 
In 2017, Huang and his colleagues demonstrated targeted imaging of glioma and tumor-
associated vasculature within the BBB using NGR-conjugated PEG-QD (NGR-QD) [77]. 
The NGR peptide is known to target CD13 transmembrane glycoprotein, which is 
overexpressed in tumor cells, and PEG was added to the QD to improve its 
biocompatibility. Although the study could not determine if NGR-QD was able to cross 
the BBB, it did successfully bind to glioma and tumor-associated vasculature and was 
detectable using fluorescence imaging. However, like the previous study by Kato et al., 
the study maintains that the cytotoxicity of QD cannot be ignored, and only low doses 
should be administered to ensure low to no toxicity of QDs to animal samples [74,77]. 
2.2.4 Nanoparticles in Drug Delivery to Biology Barriers 
There have been studies of successful drug delivery system using nanoparticles as a 
vector.  
2.2.4.1 AMT transport 
The first set of vectors target the AMT transport system for delivery. In a physiological 
environment, the cerebral endothelial cells are negatively charged due to the polarized 
distribution of carboxyl groups on glycoprotein and sulfate groups on proteoglycans on 
the plasma membrane [78,79]. With this in mind, cationic nanoparticles, such as chitosan 
and certain polymers, have been used to load drugs inside or coat the drugs from the 
outside [80–83]. Examples of cationic polymers used to load drugs inside are 
poly(propylene imine) (PPI) and poly(ethylenimine) (PEI) [82,83]. The endocytosis of 
the drug carrier is completed through AMT. Moreover, the efficiency of AMT can be 
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amplified by modifying the polymer core with cationic nanoparticles, such as 
maltodextrin nanoparticles [84].  
Apart from taking advantage of the electrostatic interaction, it is also important to note 
the lipophilic property of the plasma membrane. Naturally, substances with high 
lipophilicity have easier time interacting with the plasma membrane. A study using solid 
lipid nanoparticles as a delivery vesicle has also been successful [85]. 
Unsurprisingly, there are limitations to this delivery method. Cationic surfaces exhibit 
higher cytotoxic effects compared to their neutral counterparts; furthermore, the AMT 
transport system is non-specific, which may result in random distribution of the drug 
instead of targeted treatment [86]. 
2.2.4.2 RMT transport 
Unlike AMT, the binding interaction in RMT is more specific and has higher binding 
affinity between the ligand and the receptors. As well, the ligand does not need to be 
positively charged, thereby eliminating the increased potential of cytotoxicity. 
Out of the various receptors involved in RMT, transferrin receptors are most often used 
as they are expressed widely in the luminal membrane of the capillary endothelium [87]. 
Once the drug is loaded onto the nanoparticle vector of choice, the vector is coated with 
transferrin so that it can be picked up by the transferrin receptor [88–90].  
One major limitation of RMT transport is that there is still a potential for the vector to be 
delivered to the wrong organ as many receptors are not exclusive to the BBB. The best 
method for delivery therefore involves taking advantage of both AMT and RMT, by 
making a nanoparticle vector positively charged as well as coating it with a ligand for 
receptor-mediated transport. Previous studies have shown that the ligand for RMT can act 
as a shield to the cationic surface to improve the biocompatibility of the vector while 
maintaining the electrostatic effects, resulting in successful synergy between RMT and 
AMT [83]. 
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Chapter 3  
3 Self-illumination of Carbon Dots by Bioluminescence 
Resonance Energy Transfer 
3.1 Introduction 
Major limitations of in vivo fluorescence studies stem from the use of high-power 
external light source. As mentioned before, the cytotoxicity and tissue damage from the 
light source results in irreparable damages to the sample; furthermore, tissue 
autofluorescence and photobleaching lead to inaccurate results.  
In order to utilize BRET, which would eliminate problems arising from the external light 
source, the donor-acceptor pair must be kept in close proximity to one another. While this 
can be done through protein-protein conjugation between the bioluminescent protein and 
the fluorescent molecule, CDs are a better candidate compared to other fluorescent 
molecules as they already have surface functional groups ready for protein conjugation. 
Moreover, CDs do not denature to lose their fluorescent properties, whereas there is 
always a potential for proteins to undergo denaturation with the introduction of another 
molecule through conjugation. 
Recently, one study has developed a self-illuminating QD through conjugation of a QD 
with a synthetic luciferase [11]. While such a recombinant molecule eliminates the need 
for an external light source, the high toxicity of this QD must be acknowledged for in 
vivo studies. As discussed before, compared to QDs, CDs would be a far superior 
candidate as a photon acceptor as they exhibit good photostability and high fluorescence 
intensities like QDs, while also having good biocompatibility, which QDs lack. 
Here, we develop a method to produce self-illuminating CDs, which uses the BRET 
mechanism to achieve its self-illumination. Figure 3 demonstrates the bioconjugation of 
the CD to Rluc through carboxyl-to-amine crosslinking. The study examines different 
factors that determine the efficiency of self-illuminating CD production which include: 
different CD-to-Rluc ratios; two different crosslinkers, N’-(3-dimethylamnopropyl)-N-
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ethylcarbodiimide (EDC) and EDC with N-hydroxysuccinimide (NHS); and different 
conjugation times. 
We hypothesize that the BRET efficiency would be superior when conjugating Rluc and 
CD using EDC/NHS compared to only EDC, as EDC/NHS is a more potent coupler 
compared to EDC. Furthermore, we also hypothesize that BRET efficiency would 
increase with higher concentrations of the CD and longer conjugation times, as more 
conjugation would allow for more self-illuminating CDs to be produced, therefore 
increasing the BRET efficiency of the sample. 
 
Figure 3: EDC- or EDC/NHS-mediated conjugation of bioluminescent protein, Rluc 
to CDs. Both crosslinkers couple the free surface carboxylic acids on the CD with 
the amine group on the N-terminal of Rluc to form peptide bond. The close 
proximity between CD and Rluc after conjugation allows for BRET. 
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3.2 Materials and Methods 
3.2.1 Materials 
Citric acid, urea, EDC, and NHS were purchased from Sigma Aldrich (Oakville, 
Canada). Rluc and CTZ were purchased from Nanolight Technology (Pinetop, USA). 
3.2.2 Carbon Dot Synthesis 
This method was derived from a previously reported method, which utilizes a microwave 
oven-assisted process to produce water-soluble CDs [11]. Citric acid and urea were added 
to excess distilled water in 1:1 ratio. The solution was heated using a domestic 750 W 
microwave oven in 45 second intervals until it became dark brown clustered solid. The 
resulting solid was cooled to room temperature then frozen overnight. The frozen solid 
was then freeze dried (The Virtis Company, Gardiner, USA) for two days in order to 
isolate the CDs. 
3.2.3 Bioconjugation of Renilla Luciferase with Carbon Dot 
Two different sets of samples were prepared: one set using 10 L of 20 mM EDC and the 
other using 10 L of 20 mM EDC and 10 L of 20 mM NHS. Each set consisted of five 
different samples of different concentrations of CDs dissolved in distilled water: 0.10 
mg/mL, 0.20 mg/mL, 0.40 mg/mL, 0.80 mg/mL, and 1.20 mg/mL. The final volume of 
each samples was 400 L, and all samples were incubated for 30 min at 37 C. 2 M 
Rluc was added to each sample then further incubated at 37 C for 1 hour. Samples were 
used immediately for fluorescence study after the incubation. The procedure was repeated 
twice with different incubation periods: 6.5 hours and 24 hours. 
3.2.4 Photoluminescence Study 
All fluorescence measurements were obtained using PTI Fluorescence Master System 
(HORIBA Canada Inc.). Emission spectra from 400 nm to 700 nm of the CD and Rluc 
were measured. The excitation wavelength was set to 480 nm, the emission wavelength 
of Rluc, when measuring the emission spectrum of CD. 30 M CTZ was added to Rluc 
immediately before measuring the emission spectrum of Rluc to initiate bioluminescence. 
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Due to the short-lived nature of Rluc bioluminescence, the step size was fixed at 10 nm, 
and the integration was fixed at 0.1 s for all measurements. Bioluminescence of Rluc as a 
function of time after CTZ introduction can be found in Appendix 3. 
Immediately prior to taking the measurements, 30 M CTZ was added to the samples to 
initiate the BRET mechanism. Emission spectrum for each sample was then measured 
from 400 nm to 700 nm with the external light source turned off.  
3.3 Results 
3.3.1 Bioluminescence of Renilla Luciferase and 
Photoluminescence of Carbon Dot 
The maximum bioluminescence intensity of Rluc (2.0 M) was observed at 480 nm as 
shown in Figure 4a. The small inset in Figure 4a demonstrates the 37.5 kDa Rluc on 
SDS-PAGE gel. The bioluminescence of Rluc increased linearly as the concentration of 
CTZ increased from 0 M to 13.6 M and then plateaued with higher concentration of 
CTZ following the Michaelis-Menten model as shown in Figure 4b. Michaelis constant 
(Km) was calculated to be 2.83 M; therefore, 30 M CTZ was used for 2 M Rluc as it 
is normal to add substrate within 10–20 times of Km to reach maximum reaction velocity. 
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Figure 4: (a) Bioluminescence of 2.0 M Rluc reacting with 7.8 M CTZ. The small 
inset shows the purified Rluc on the SDS-PAGE gel. (b) Bioluminescence intensity 
as a function of the concentration of CTZ, its substrate. 
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Due to the small nature of the CD, CD characterization was done using TEM as shown in 
the small inset of Figure 5, with average particle size being estimated at 13 ± 3 nm. The 
photoluminescence of free CD is shown in Figure 5, and the UV-vis absorption spectra of 
CDs at different concentrations is shown in Appendix 1. All CD samples displayed broad 
absorption spectra with the same absorbance peaks at 270 nm, 340 nm, and 405 nm, 
which matches the absorbance peaks reported in previous study; furthermore, the CDs 
have excitation-wavelength-dependent PL properties within maximum yield at about 
14% [20]. Since the emission of Rluc is centered at 480 nm, the photoluminescence of 
CD was measured with an excitation wavelength of 480 nm. The maximum emission of 
CD was observed to be around 557 nm as shown in Figure 5. 
 
Figure 5: Photoluminescence of CDs under an excitation wavelength of 480 nm. 
TEM micrograph of CDs is shown in the small inset of the figure. 
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3.3.2 The Factors on the Performance of BRET 
3.3.2.1 EDC- and EDC/NHS-mediated conjugations 
Two crosslinking agents, EDC and EDC/NHS, were used to conjugate Rluc onto CDs 
through amide bond. Conjugation time frame was fixed at 6.5 hours while the 
concentration of the CD was also fixed at 0.20 mg/mL. The resulting emission spectra 
can be seen in Figure 6. While the samples conjugated with EDC retained a broad peak, a 
complete loss of fluorescence can be observed for samples conjugated with EDC/NHS. 
 
Figure 6: Emission spectra of EDC- and EDC/NHS-mediated conjugation of Rluc 
and CD. The concentration of CD was fixed at 0.20 mg/mL, and the conjugation 
time was fixed at 6.5 hours. 
3.3.2.2 Different concentrations of CD 
Five different concentrations of CD were used to produce self-illuminating CD: 0.10 
mg/mL, 0.20 mg/mL, 0.40 mg/mL, 0.80 mg/mL and 1.20 mg/mL. Emission spectrum 
from three of the five concentrations of CD are shown in Figure 7. The conjugation time 
was fixed at 6.5 hours and EDC was used as the conjugation factor. A sharp peak can be 
observed from the sample using 0.10 mg/mL, while a broad peak can be observed from 
the sample using 0.20 mg/mL. Although not pictured, 0.40 mg/mL and 0.80 mg/mL 
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displayed broad peak similar to that shown in 0.20 mg/mL. Lastly, the sample using 1.20 
mg/mL had complete loss of fluorescence. 
 
Figure 7: Emission spectra of samples using different concentrations of CDs. EDC 
was used as the coupling agent, and the conjugation time was fixed at 6.5 hours. 
3.3.2.3 Different conjugation times 
Three different conjugation times were used when conjugating Rluc to the CD: 1 hour, 
6.5 hours, and 24 hours. The concentration of the CD was fixed at 0.20 mg/mL, and EDC 
was used as the coupling agent for the conjugation. The resulting emission spectrum is 
shown in Figure 8. One sharp peak is observed for 1 hour conjugation; a broad peak is 
observed for 6.5 hours of conjugation; and finally, a lack of peak is observed for 24 
hours. 
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Figure 8: Emission spectra of samples produced using different conjugation times. 
The concentration of the CD was fixed at 0.20 mg/mL, and EDC was used as the 
coupling agent. 
3.3.2.4 BRET profile and efficiency of BRET 
Figure 9a displays the BRET profile of 6.5 hours of conjugation of 2.0 M Rluc and 0.20 
mg/mL CD with EDC as coupling agent. The black line is the emission measurement 
taken using the sample, while the red and blue lines, which represent Rluc and CD 
respectively, were obtained by using multi-peak fitting software. The small inset of 
Figure 9a is photos of Rluc compared to CD-Rluc, the self-illuminating CD without any 
external high-power light supply. BRET profiles of 6.5 hours of conjugation of 2.0 M 
Rluc and 0.40 mg/mL CD and 0.08 mg/mL CD with EDC as the coupling agent can be 
found in Appendix 2. 
BRET efficiency was calculated using the following equation [11] 
𝐸𝐵𝑅𝐸𝑇 =
𝐼𝐶𝐷𝑠
𝐼𝑅𝑙𝑢𝑐
 , 
where ICDs is the integrated emission within the range of 450–650 nm from CDs caused 
by the BRET, and IRluc is the integrated emission within the range of 390–550 nm from 
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bioluminescence of Rluc. Higher BRET efficiency represents better energy transfer from 
Rluc to CDs. Figure 9b shows that the BRET efficiency increases linearly with increasing 
concentrations of CDs from 0.20 mg/mL to 0.80 mg/mL. 
 
 
Figure 9: (a) BRET profile of sample made using EDC as coupling agent with 0.20 
mg/mL of CD and 2 M Rluc for 6.5 hours of incubation. The black line represents 
the emission spectrum of the sample, or the BRET profile. The red and blue line, 
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which represents Rluc and CD respectively, were obtained using multi-peak fitting 
software. The small inset is the photo of 2 M Rluc and CD-Rluc complex. (b) 
BRET efficiency as a function of CD concentration. 
3.4 Discussion 
It is no with doubt that the bioconjugation of Rluc to CD is vital to achieve the self-
illuminating CD through the BRET mechanism. Surprisingly, we observed that 
EDC/NHS conjugation resulted in a complete loss of fluorescence. It is important to note 
that both EDC- and EDC/NHS-mediated conjugation is non-selective in that the coupling 
agents conjugate any free carboxylic acid to any free amine group. Because of their non-
selective nature, conjugation can occur between the carboxylic acid group on the CD with 
either the amine on the N-terminal of Rluc or the amine on lysine residues of the Rluc 
[91]. Because Rluc is a small protein, conjugation of the CD in the middle of the protein 
may lead to denaturation as described in previous literature using different small proteins 
[54,92]. Furthermore, a previous study demonstrated that protein conjugation at lysine 
residues of Rluc may be fatal to protein structure and may result in loss of function [91]. 
Another study has already shown that mutations involving certain lysine residues of Rluc 
led to decreased in function to further support this event [93]. 
A similar problem may have arisen with high CD concentration and longer conjugation 
period. We observed that fluorescence is completely lost with CD concentration of 1.20 
mg/mL and conjugation time of 24 hours. With more CD present, there would have been 
a higher possibility of more CD-lysine residue conjugation, leading to loss of 
fluorescence. Similarly, with longer conjugation time, there would be an increased 
potential for CD to conjugate at lysine residues as well as the N-terminal of Rluc. 
Although EDC is a less potent coupling agent, with high enough concentration of the CD 
and long enough conjugation time, conjugation at lysine residues of Rluc are not 
preventable as supported by experimental data. 
On the other hand, no BRET phenomenon is observed for low concentration of the CD 
and short conjugation time. Only a sharp peak representing the Rluc fluorescence can be 
observed as seen in Figures 5 and 6. This can be explained by the kinetic nature of bond 
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formation. For bonds to form, molecules must collide with one another at a correct angle; 
however, with low concentration of the CD, the probability of collision decreases, and 
with short conjugation time, the potential for collision also decreases. 
The BRET phenomenon was observable for 0.20–0.80 mg/mL of CD conjugated with 2 
M Rluc with EDC as coupling agent for 6.5 hours of conjugation. The BRET efficiency 
was observed to be linearly correlated within the said range of CD concentrations. As 
mentioned earlier, when the concentration of the CD is increased beyond 0.80 mg/mL, 
the fluorescence function of Rluc is lost due to overwhelming conjugation at the lysine 
residue. Previous studies of BRET using organic dyes conjugated with a bioluminescence 
protein also showed that non-specific BRET signals tend to increase linearly with 
increasing acceptor concentrations [94,95]. 
3.5 Conclusion 
In conclusion, water-soluble CDs with average particle size of 13 ± 3 nm were produced 
using microwave oven-assisted process. In order to achieve self-illumination of the CD, 
Rluc, a bioluminescent protein, was conjugated onto the CDs, as the BRET mechanism is 
distance dependent. Rluc bioluminesces at 480 nm, which falls within the range of the 
CD absorption spectrum. CD emits at 557 nm when excited with a photon at 480 nm. The 
ideal concentration of Rluc substrate, CTZ, was investigated, and the Michaelis constant 
was calculated to be around 2.83 M when using 2 M Rluc. Three different factors 
leading to conjugation were investigated: different coupling agents, different 
concentrations of the CD, and different conjugation times. Our study indicated that BRET 
efficiency increases linearly with increasing concentrations of CD from 0.20 mg/mL to 
0.80 mg/mL with EDC as the conjugating agent at 6.5 hours of conjugation. 
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Chapter 4  
4 Investigation of Carbon Dot Crossing Bovine Blood 
Retina Barrier 
4.1 Introduction 
With an increasing population suffering from various neurodegenerative diseases and 
retinal degenerative diseases, it is crucial to investigate different methods of diagnosing 
and treating such diseases. The first step in the development of these methods would be 
to uncover more substances that are able to successfully cross the biological barriers.  
Although different nanoparticles have been shown to cross the BBB, there are limitations 
observed in such studies. QDs are known to be cytotoxic and therefore are not ideal for in 
vivo studies. Although such a problem can be resolved by coating the QD with 
biocompatible materials, there is potential for the biocompatible material to degrade 
faster than the QD, which would lead to exposure of the toxic material. Though silica 
nanoparticles are biocompatible, they are not fluorescent and require an additional step to 
load them with traditional dyes. 
CDs would be an ideal candidate for the study as they are fluorescent and biocompatible; 
furthermore, it is easy to modify CDs through surface conjugation for targeted studies. 
The present study aims to investigate if CDs are able to cross biological barriers. As 
bovine retina is easier to obtain compared to an intact bovine BBB system, bovine retina 
will be used to represent the biological barrier system for this investigation.  
4.2 Materials and Methods 
4.2.1 Materials 
Citric acid, urea, sterile phosphate buffered saline (PBS), and Triton X-100 were 
purchased from Sigma Aldrich (Oakville, Canada). Bovine eyes were graciously donated 
by Mount Brydges Abattoir (London, Canada). 
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4.2.2 Carbon Dot Synthesis 
This method was derived from a previously reported method, which utilizes a microwave 
oven-assisted process to produce water-soluble CDs [11]. Citric acid and urea were added 
to excess distilled water in 1:1 ratio. The solution was heated using domestic 750 W 
microwave oven in 45 second intervals. The solution was heated until it became dark 
brown clustered solid. The resulting solid was cooled to room temperature then frozen 
overnight. The frozen solid was then freeze dried (The Virtis Company, Gardiner, USA) 
for two days in order to isolate the CDs. 
4.2.3 Preparation of Bovine Retina 
The following protocol was derived from previous studies [96,97]. Fresh bovine eyes 
were obtained from the local abattoir and used within 3 hours. First, extraocular tissue 
was removed from the eyes. The images of bovine eyes before and after extraocular 
tissue removal is shown in Figure 10. An incision of 8–10 mm was made along the 
border of the cornea and sclera using a surgical blade. The incision was extended around 
the entire eye using scissors, and the anterior segment and the vitreous was separated 
from the neural retina. The resulting structure will be referred to as “eye cup” from herein 
forward. An image of eye cup is shown in Figure 11. 1 mL of 1mg/mL CD in distilled 
water was added to the inside of the eye cup. The eye cup was incubated for 1.5 hours at 
37 C. After the incubation, the CD solution was removed from the eye cup, and the 
inside was rinsed three times using 3 mL of distilled PBS. From the inside, the neural 
retinal layer was peeled from the eye cup and placed in the tissue grinder tube on ice. 
Next, the choroid layer was peeled from the eye cup and placed in another tissue grinder 
tube on ice. Both tissue samples were then homogenized on ice in 500 L PBS 
containing 2% Triton X-100. The samples were centrifuged at 5000 rpm for 20 minutes 
at 4 C, and the supernatants were collected and placed on ice in preparation for 
fluorescence study. 
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Figure 10: (a) Back of the bovine eye before extraocular tissue removal. (b) Back of 
the bovine eye after extraocular tissue removal. (c) Front of the bovine eye before 
extraocular tissue removal. (d) Front of the bovine eye after extraocular tissue 
removal. 
 
Figure 11: Experimental eye cup. Extraocular tissues have been removed and, the 
anterior segment and the vitreous are removed in preparation for CD treatment. 
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4.2.4 Fluorescence Study 
All fluorescence measurements were obtained using PTI Fluorescence Master System 
(HORIBA Canada Inc.), and the excitation wavelength was fixed at 430 nm, where it 
corresponds with the highest absorption peak of CD (See Appendix 1). First, the emission 
spectrum of the CD was measured. The emission spectra of the neural retinal layer and 
the choroid layer without any treatment were measured. The emission spectra of all 
samples were then measured. 
4.3 Results 
4.3.1 Neural Retinal Layer 
Figure 12 shows three lines: the green dotted line representing free CD, the blue line 
representing the neural retina layer before CD treatment, and the orange line representing 
the neural retina layer after CD treatment. In the initial CD photoluminescence spectrum, 
one peak was observed centered at 530 nm. No distinct peak was observable in the neural 
retina layer prior to CD treatment, although some fluorescence was observed. The neural 
retinal layer after CD treatment displayed a distinct peak also centered at 530 nm as seen 
in the free CD spectrum. 
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Figure 12: Emission spectra of free CD (green), neural retinal layer before CD 
treatment (blue), and neural retinal layer after CD treatment (orange). CD 
treatment consisted of 1 mL of 1 mg/mL CD incubated for 1.5 hours inside the eye 
cup. 
4.3.2 Choroid Layer 
Figure 13 shows three lines: the green dotted line representing free CD, the blue line 
representing the choroid layer before CD treatment, and the orange line representing the 
choroid layer after CD treatment. In the initial CD photoluminescence spectrum, one 
peak was observed centered at 530 nm. Although no sharp peaks were observable in the 
choroid layer prior to CD treatment, two weak and broad peaks can be observed centered 
around 500 nm and 590 nm. The choroid layer after CD treatment displayed a broad 
fluorescent area with three peaks centered around 500 nm, 530 nm, and 590 nm. 
 
Figure 13: Emission spectra of free CD (green), choroid layer before CD treatment, 
(blue) and choroid layer after CD treatment (orange). CD treatment consisted of 1 
mL of 1 mg/mL CD incubated for 1.5 hours inside the eye cup. 
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4.4 Discussion 
By only observing the results from the neural retina layer, it is not possible to conclude if 
the CD was successful in crossing the BRB. Because the CD was incubated inside the eye 
cup, there is potential for the CD to stick to the endothelial cells of the neural retina layer. 
As seen in Figure 12, the emission spectrum of the neural retina layer after CD treatment 
displays fluorescent peak that corresponds to the CD emission spectrum, although there is 
a decrease in fluorescence intensity. The decrease in fluorescence intensity could have 
resulted from the CD that did not cross or adhere to the neural retina layer. It is 
worthwhile to note that when comparing the emission spectra of the neural retina layer 
before and after the CD treatment, there is a loss of fluorescence at certain wavelengths 
after the treatment. While certain pigments may have been lost during the tissue 
homogenization process, studies investigating the relationship between CDs and the 
maintenance of BRB structure should be performed. 
The results from the choroid layer are surprising, as it seems that some CD was able to 
cross over the neural retina layer into the choroid layer. It is also interesting that while the 
some of the initial fluorescence of neural retina layer was lost after CD treatment, the 
initial fluorescence of choroid layer seems to be amplified by the CD fluorescence signal. 
When observing the emission spectrum of the choroid layer after the CD treatment, three 
peaks can be observed; two peaks, which match the initial weaker peaks seen in the 
choroid layer, and the middle peak, which corresponds with the CD emission peak.  
4.5 Conclusion 
In summary, the study investigated the ability of CDs to cross biological barriers. Due to 
the readily available nature of bovine eyes, the BRB model was used to perform this 
study. While it was not surprising to receive CD emission signals from the neural retina 
layer after CD treatment of the inside of the eye, it is interesting to be able to observe CD 
fluorescence signal from the choroid layer, which signifies that CD had to cross over the 
neural retina layer in order to be present in the choroid layer. The neural retina layer 
represents the iBRB, which has been shown to be similar to the BBB in structure and 
permeability; therefore, it would be of interest to conduct similar studies with a BBB 
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model to examine if the CD is able to also cross the BBB. More supporting data would be 
required to conclude that CDs can indeed cross biological barriers; however, this 
investigation acts as a steppingstone for further examination. 
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Chapter 5  
5 Summary and Future Work 
5.1 Summary 
FNPs are good candidates for fluorescence studies due to their brightness, good 
photostability, good biodistribution, and easily modifiable surface. In particular, CDs are 
ideal amongst the FNPs due to their biocompatibility and the different excitation-
emission pairings available. Although CDs can be used freely in the majority of 
fluorescence studies, two studies were performed in order to open new doors for CDs to 
be used in further fluorescence studies. 
The first investigation consisted of the development of self-illuminating CDs. For many 
fluorescence studies, especially the ones that examine protein-protein interactions, FRET 
is the most commonly used method. Although FRET is distance dependent and therefore 
useful when studying the interactions between two molecules, the necessity of a high-
power external light source poses many limitations, such as photocytotoxicity, tissue 
damage, photobleaching, and autofluorescence. Such limitations can result in inaccurate 
data as well as cause irreparable damage to the sample. A self-illuminating CD, which 
uses the BRET mechanism instead of FRET, eliminates the need for a high-power 
external light source, thereby resolving all limitations stemming from it. The 
development of a self-illuminating CD involved three different factors: different coupling 
agents, different CD concentrations, and different conjugation times. The ideal conditions 
for developing a self-illuminating CD was found to be 6.5 hours of conjugation using 
EDC as the coupling agent with 0.20–0.80 mg/mL of CD. The BRET efficiency was 
calculated and observed to be linearly correlated with increasing concentrations of CD. 
The second investigation was an examination of the ability of CDs in crossing biological 
barriers. Two different barriers were introduced: the BBB and the BRB. Each barrier, 
while extremely crucial in normal settings, also poses difficulties when diagnosing and 
treating degenerative diseases of the brain or the retina. The rare ability to cross these 
biological barriers is significant as it opens potential for the development of diagnostic 
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tools as well as a drug delivery system to structures beyond the barriers. Although 
different NPs have been found to be able to cross the BBB, CDs have yet to be studied. 
CDs would be an ideal candidate for studying the biological barrier due to their 
fluorescence characteristics and good biocompatibility. Because of the readily available 
nature of bovine eyes from abattoirs, the BRB model was used to study the ability of CDs 
in crossing biological barriers. Although the fluorescence studies conducted in this 
investigation suggests that CDs are able to cross the iBRB into the oBRB, more 
supporting data using different methods would be necessary before concluding that CDs 
are able to cross biological barriers. 
The introduction of a self-illuminating CD and the potential of CDs in crossing biological 
barriers opens new doors in the biomedical field of research. The first leads to in vivo 
studies where the external light source is problematic; and the second leads to studies 
involving biological barriers, whether they involve diagnosis or drug delivery. 
5.2 Limitations and Future Work 
5.2.1 Self-illuminating CD 
The major limitation in the self-illuminating CD study is the lack of methods to isolate 
the self-illuminating CD from the sample, which consists of free Rluc, free CD, and the 
self-illuminating CD. After the conjugation step is completed, there would be 
unconjugated Rluc and CD left over. To use the self-illuminating CD in fluorescence 
studies, isolation and purification of the CD would be necessary to ensure high 
concentration and lack of impurities that could interfere with the results. 
Furthermore, although Rluc was used as the bioluminescent protein for the BRET 
pairing, recently synthetically developed luciferases have even better photostability as 
well as brighter intensities while being smaller in size. As well, the substrate used by 
these new luciferases is also different and have shown better biodistribution and stability 
in in vivo settings. Future work could involve switching out Rluc for these newer 
alternatives to make a more powerful self-illuminating CD. 
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More generally, the compatibility of the CD and bioluminescent proteins opens new 
doors in developing non-invasive biosensors. As BRET is distance dependent, 
combination of a multicolor CD and the BRET technique could be used in conjunction to 
measure protein-protein or protein-nucleic acid interactions. 
5.2.2 CD crossing BRB 
The major limitation in this study is the lack of supporting evidence to demonstrate that 
CDs can cross the BRB. Further studies involving TEM or SEM imaging to visualize the 
CD in the different layers of BRB would be interesting and act as a strong supporting 
evidence. More studies should be conducted to investigate if the presence of the CD 
results in damage in the neural retina layer, as loss of fluorescence in the neural retina 
layer after the CD treatment could be observed in Figure 13. 
If the CD is able to cross the biological barrier, it would be interesting to see if the self-
illuminating CD could also cross the barrier. As discussed before, fluorescence imaging 
involving an external light source usually leads to inaccurate results and irreparable 
damages to the samples. It would be beneficial to be able to use BRET techniques in 
order to conduct these fluorescent studies compared to traditional FRET techniques or 
fluorescent imaging. 
Targeting studies with CDs would be easier to implement as CDs have multiple surface 
groups that are ready to be conjugated without potentially losing its fluorescence. Similar 
to a study by Huang and his colleagues, CDs could be modified with specific ligands for 
receptors that are overexpressed in cancerous cells [77]. Because CDs exhibit far greater 
biocompatibility compared to QDs, they would be an ideal substitute for such in vivo 
studies. 
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Appendices 
Appendix 1: UV-vis absorption spectrum of different concentrations of CDs. 
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Appendix 2: (a) BRET spectrum of sample made through EDC-mediated 
conjugation of 0.40 mg/mL CD and 2 M Rluc for 6.5 hours. (b) BRET spectrum of 
sample made through EDC-mediated conjugation of 0.80 mg/mL CD and 2 M Rluc 
for 6.5 hours. The black line represents the BRET profile of the sample; the red line 
and the blue line were obtained using multi-peak fitting and represent 
bioluminescence of Rluc and photoluminescence of CD respectively. 
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Appendix 3: Bioluminescence of Rluc as a function of time after introduction of 
CTZ 
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